Lawrence E Morris
Overview
Explore the profile of Lawrence E Morris including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
1271
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Solh M, Solomon S, Morris L, Zhang X, Holland H, Bashey A
Leuk Res
. 2020 Mar;
93:106318.
PMID: 32127177
The fludarabine, high dose cytarabine and G-CSF with or without idarubicin combination regimen, referred to as FLAG+/-Ida, is commonly used as a salvage regimen for relapsed/refractory AML but its use...
22.
Solomon S, Solh M, Jackson K, Zhang X, Holland H, Bashey A, et al.
Bone Marrow Transplant
. 2019 Sep;
55(1):189-198.
PMID: 31527818
Due to perceived intolerance, many elderly AML patients do not receive therapy, and few are considered for hematopoietic cell transplantation (HCT). To better understand "real-world" outcomes, 323 consecutive AML patients ...
23.
Solomon S, Solh M, Zhang X, Morris L, Holland H, Bashey A
Biol Blood Marrow Transplant
. 2019 Jun;
25(11):2211-2216.
PMID: 31247313
Although myeloablative conditioning (MAC) before haploidentical donor transplant (HIDT) with post-transplant cyclophosphamide is being increasingly used, the optimal preparative regimen remains unclear. In our initial trial, the feasibility of HIDT...
24.
Karam E, Laporte J, Solomon S, Morris L, Zhang X, Holland H, et al.
Biol Blood Marrow Transplant
. 2019 Jun;
25(10):2054-2060.
PMID: 31173900
T cell replete HLA-mismatched haploidentical transplantation (HIDT) with post-transplant cyclophosphamide is increasingly becoming an acceptable treatment approach for patients lacking timely access to a suitably matched related donor transplant (MRDT)...
25.
Solh M, Dickhaus E, Solomon S, Morris L, Zhang X, Holland H, et al.
Bone Marrow Transplant
. 2019 Apr;
54(11):1756-1763.
PMID: 30953027
Fever is a common early complication after infusion of stem cells in patients undergoing T-replete HLA haploidentical transplantation using post-transplant cyclophosphamide (PTCY). We analyzed the records of 172 haploidentical transplant...
26.
Solomon S, Sizemore C, Ridgeway M, Zhang X, Brown S, Holland H, et al.
Bone Marrow Transplant
. 2018 Dec;
54(8):1218-1226.
PMID: 30518977
Initial therapy of chronic GVHD (cGvHD) has not changed for over three decades, despite limited efficacy and long-term toxicity. We have previously shown in a small pilot study the feasibility...
27.
Solh M, Solomon S, Morris L, Zhang X, Holland H, Bashey A
Biol Blood Marrow Transplant
. 2018 Sep;
25(3):606-612.
PMID: 30244109
The impact of conditioning intensity on different disease risk index (DRI) groups has not been evaluated. We retrospectively analyzed acute myelogenous leukemia (AML)/myelodysplastic syndrome (MDS) hematopoietic cell transplantation (HCT) recipients...
28.
Zeidner J, Foster M, Blackford A, Litzow M, Morris L, Strickland S, et al.
Leuk Res
. 2018 Aug;
72:92-95.
PMID: 30118897
No abstract available.
29.
Bashey Z, Zhang X, Brown S, Jackson K, Morris L, Holland H, et al.
Bone Marrow Transplant
. 2018 Mar;
53(6):756-763.
PMID: 29523888
Allografting from HLA-haploidentical donors (HID) is being increasingly utilized worldwide for patients lacking a conventional matched donor. However, its efficacy in older patients with AML and MDS is unclear. We...
30.
Solomon S, Zhang X, Holland H, Morris L, Solh M, Bashey A
Biol Blood Marrow Transplant
. 2018 Jan;
24(6):1237-1242.
PMID: 29378303
Available evidence from large registry studies has shown inferior survival for black adult patients following both unrelated donor and cord blood transplantation. Post-transplant cyclophosphamide (PTCy)-based haploidentical donor transplantation (HIDT) is...